Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RRM1 inhibition sensitizes lung adenocarcinoma to decitabine treatment

ABSTRACT: Aberrant DNA methylation has been implicated in tumorigenesis and development of lung cancer. However, Nucleoside analog DNA methyltransferase inhibitors have demonstrated clini-cal utility in treatment of myelodysplastic syndrome and acute myeloid leukemia, the drugs have not shown commensurate clinical efficacy in solid tumors. Mechanisms mediating the primary resistance to DNA hypomethylating agents in solid tumors are not fully understood. Here, we hy-pothesized that factors that limit incorporation of nucleoside analog DNA methyltransferase in-hibitors in genomic DNA may underlie the tumor cell intrinsic primary resistance to decitabine in lung cancer. We found that RRM1 expression levels were inversely correlated with decitabine incorporation rates detected by LC-MS/MS. RNA interference mediated depletion of RRM1, the catalytic subunit of ribonucleotide reductase (RNR), or pharmacological inhibition of RNR signifi-cantly potentiated inhibition of lung cancer cell clonogenic survival in vitro and xenograft growth in vivo by decitabine treatment. Additionally, RRM1 knockdown or pharmacological inhibition of RNR enhanced decitabine mediated upregulation of tumor suppressor genes and STING-related im-mune response. RNR inhibition led to increased incorporation of decitabine into genomic DNA by reducing the availability of dCTP. These findings nominate the promising combination therapy of decitabine and RNR inhibitors as being ripe for further clinical translation.

ORGANISM(S): Homo sapiens

PROVIDER: GSE292076 | GEO | 2026/03/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Identification of genes regulated by loss of RRM1 in Ewing sarcoma cells.

Project description:Ribonucleotide reductase (RNR), which is composed of RRM1 and RRM2 subunits, is the rate limiting enzyme in the synthesis of deoxyribonucleotides and required for DNA replication and DNA damage repair. We used a conditional knockout (CRISPR/Cas9) and rescue approach to target RRM1 in Ewing sarcoma cells and identify downstream pathways impacted by the loss of RNR activity. RNA-seq analysis was performed at times 0 and 48 hours after removal of doxycycline from cell culture media, which results in loss of the RRM1 protein.

2023-08-23 | GSE215881 | GEO

Gene expression profiles of NCI-H929 cells after knockdown of RRM1 and RRM2

Project description:Purpose: Overexpression or polymorphisms of ribonucleotide reductase (RR) are described in many solid tumors, and its expression is highly correlated with survival. However, the biologic significance in multiple myeloma (MM) has not yet been elucidated. Here, we identify the role of RR in MM pathogenesis. Experimental Design: Here we studied the potential utility of RRM1 knockdown effect in multitple myeloma in vitro and in vivo. Results: Knockdown of RRM1 (large subunit) triggered significant growth inhibition, associated with apoptotic cells death, in MM cells, regardless of the existence of bone marrow microcnrivonment. To validate the role of RRM1 of xenograft model, tumor growth was significantly reduced in RRM1-knocked-down MM cells versus control MM cells. Gene expression profiling showed that p53 regulated genes were upregulated after RRM1 knockdown. Immunoblot and QRT-PCR validated that p53 pathways were acviated as well. Clofarabine (CLO), a purine nucleoside analog which inhibits both DNA polymerases and RRM1, is a potential therapeutic agent in MM. CLO induced growth arrest in p53 wild-type cell lines, but not in p53 mutant or null cells. Moreover, CLO treatment with combined with DNA damaging agents triggered synergetic cell death even in p53 mutant MM cells. Conclusions: Our results therefore demonstrate that RRM1 is a novel therapeutic target in patients with MM, and provide the basis for clinical evaluation of RRM1 inhibitor, alone or in combination with DNA damaging agents, to improve patient outcome.

2017-03-01 | GSE93425 | GEO

A high-throughput screen of inactive X chromosome reactivation identifies the enhancement of DNA demethylation by 5-aza-2’-dC upon inhibition of ribonucleotide reductase-wide

Project description:Background: DNA methylation is important for maintenance of the silent state of genes on the inactive X chromosome (Xi). Here, we screened for siRNAs and chemicals that reactivate an Xi-linked reporter in the presence of 5-aza-2’-deoxycytidine (5-aza-2’-dC), an inhibitor of DNA methyltransferase 1, at a concentration that, on its own, is not sufficient for Xi-reactivation. Results: We found that inhibition of ribonucleotide reductase (RNR) induced expression of the reporter. RNR inhibition potentiated the effect of 5-aza-2’-dC by enhancing its DNA incorporation, thereby decreasing genome-wide DNA methylation levels. Since both 5-aza-2’-dC and RNR-inhibitors are used in the treatment of hematological malignancies, we treated myeloid leukemia cell lines with 5-aza-2’-dC and the RNR inhibitor hydroxyurea, and observed synergistic inhibition of cell growth and decreases in genome-wide DNA methylation. Conclusions: Taken together, our study identifies a drug combination that enhances DNA demethylation by altering nucleotide metabolism. We demonstrate that XCR assays can be used to optimize epigenetic activity of drug combinations. Reduced representation bisulfite sequencing (MspI,~40-220bp size fraction) of murine and human cells.

2015-08-25 | E-GEOD-72295 | biostudies-arrayexpress

Expression profiling of DNMT1 inhibitors in HCT116 cells

Project description:Epigenetic changes accompany tumorigenesis and are required for tumor maintenance. Modulation of DNA methylation state, histone acetylation, and histone methylation, as well as reversal of disease-associated epigenetic state aberrations, can be disruptive to malignant disease progression. We produced lipophilic prodrugs of decitabine, which is a DNA methyltransferase inhibitor and is efficacious in treatment of myelodysplastic syndromes when dosed subcutaneously. Comparison of parent and prodrug activities in vitro and in vivo revealed comparable effects and unveiled several novel features of nucleoside analog molecular activity in vitro. HCT116 were treated for 72 hour with Decitabine, Azacytidine and various prodrugs in duplicates at different dose concentrations. Cells were also treated with DMSO as control (quadrpulets), RNA was extracted and samples were hybridized to Affymetrix Hu133plus 2.0 arrays.

2011-12-01 | E-GEOD-30985 | biostudies-arrayexpress

A high-throughput screen of inactive X chromosome reactivation identifies the enhancement of DNA demethylation by 5-aza-2’-dC upon inhibition of ribonucleotide reductase-wide

2015-08-25 | GSE72295 | GEO

Expression profiling of DNMT1 inhibitors in HCT116 cells

2011-12-01 | GSE30985 | GEO

Histone deacetylase inhibitors target regulators of DNA replication and the cellular response to DNA replication stress in Ewing sarcoma cells

Project description:DNA replication stress is common feature of multiple tumor types. Histone deacetylases (HDAC) regulate diverse pathways in cancer cells and recent work has identified that HDAC inhibitors downregulate the expression of multiple proteins with critical roles in DNA replication and the cellular response to DNA replication stress, including the RRM1 and RRM2 subunits of ribonucleotide reductase (RNR), CHK1, and WEE1. RNA-seq analysis was performed on a Ewing sarcoma cell line to determine the effects of HDAC inhibitors on the transcriptome.

2025-06-03 | GSE280573 | GEO

Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia

Project description:The FDA-approved DNA hypomethylating agents (DHAs) like 5-azacytidine (5AC) and decitabine (DAC) demonstrate efficacy in the treatment of hematologic malignancies. Despite previous reports that showed histone acetylation changes upon using these agents, the exact mechanism underpinning these changes is unknown. In this study, we investigated the relative potency of the nucleoside analogs and non-nucleoside analogs DHAs on DNA methylation reversal using DNA pyrosequencing. Additionally, we screened their effect on the enzymatic activity of the histone deacetylase sirtuin family (SIRT1, SIRT2, SIRT3, SIRT5 and SIRT6) using both recombinant enzymes and nuclear lysates from leukemia cells. The nucleoside analogs (DAC, 5AC and zebularine) were the most potent DHAs and increased the enzymatic activity of SIRT6 without showing any significant increase in other sirtuin isoforms. ChIP-Seq analysis of bone marrow cells derived from six acute myeloid leukemia (AML) patients and treated with the nucleoside analog DAC induced genome-wide acetylation changes in H3K9, the physiological substrate for SIRT6. Data pooling from the six patients showed significant acetylation changes in 187 gene loci at different chromosomal regions including promoters, coding exons, introns and distal intergenic regions. Signaling pathway analysis showed that H3K9 acetylation changes are linked to AML-relevant signaling pathways like EGF/EGFR and Wnt/Hedgehog/Notch. To our knowledge, this is the first report to identify the nucleoside analogs DHAs as activators of SIRT6. Our findings provide a rationale against the combination of the nucleoside analogs DHAs with SIRT6 inhibitors or chemotherapeutic agents in AML due to the role of SIRT6 in maintaining genome integrity and DNA repair.

2020-07-28 | GSE152804 | GEO

Project description:Incorporation of a nucleoside analog maps genome repair sites in post-mitotic human neurons

| PRJNA699309 | ENA

The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity

Project description:Checkpoint kinase 1 (CHK1) is critical for cell survival under replication stress (RS). CHK1 inhibitors (CHK1i’s) in combination with chemotherapy have shown promising results in preclinical studies but have displayed minimal efficacy with substantial toxicity in clinical trials. To explore combinatorial strategies that can overcome these limitations, we perform an unbiased high-throughput screen in a non-small cell lung cancer (NSCLC) cell line and identify thioredoxin1 (Trx1), a major component of the mammalian antioxidant-system, as a determinant of CHK1i sensitivity. We establish a role for redox recycling of RRM1, the larger subunit of ribonucleotide reductase (RNR), and a depletion of the deoxynucleotide pool in this Trx1-mediated CHK1i sensitivity. Further, the TrxR inhibitor auranofin, an approved anti-rheumatoid arthritis drug, shows a synergistic interaction with CHK1i via interruption of the deoxynucleotide pool. Together, we show a pharmacological combination to treat NSCLC that relies on a redox regulatory link between the Trx system and mammalian RNR activity.

2024-04-04 | GSE263176 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data